Can single-cell genomics lead to a new wave of drug targets? Celsius Therapeutics thinks so
Wednesday, July 25, 2018 - 13:36
in Health & Medicine
The start-up, based on the work of Broad Institute scientist Aviv Regev, has raised $65 million to develop therapies for cancer and autoimmune disease